Hildred Capital’s Post

Are you aware of the recent developments in the EU, UK, and Switzerland? Stay informed with the latest policy updates in Europe, including👇 👉 The EU’s Global Health Strategy 👉 Revisions to the UK regulatory framework for medical devices and strategy 👉 EU and Swiss relations 👉 And key updates from Swissmedic and the Federal Office of Public Health. Learn more >  https://bit.ly/3yoRK6q #HealthStrategy #UKregulations #MedicalDevices

#Test #Isolate #Treat #Repeat #Frequently especially in seasons with a higher prevalence of Respiratory Diseases in circulation. How can we build decentralized digital infrastructure for Rapid Diagnsotic Testing, that can scale, so that earlier intervention can prevent hospitalization and the spread of infectionous disease? #IoTDX #EdgeDX

During the years PentaBase has had a great collaboration with Eureka Network and the Innovation Fund Denmark on several projects optimizing the diagnostics of cancer. This has resulted in that PentaBase now have what we believe is the world's most sensitive portfolio for detecting circulating tumor DNA (ctDNA) with limit of detection down to 0.002% using standard qPCR. In other words are we able to find very little cancer DNA hidden among healthy DNA enabling sensitive monitoring of cancer treatment efficiencies and early detection of relapse of cancers. In the article below this, the strength of collaboration and other of our new breakthrough inventions are briefly discussed.

We're excited to share the insights from the session 'Alliances for Prevention: Biopharma, Patients, and Digital Technology' at #Anthropy23, conducted by our colleagues from Adelphi Group. They delved into the significance and challenges of prevention as a health strategy, emphasizing its role in optimizing resources and enhancing both societal health and individual quality of life. Dive into the details with us! #Biopharma #Partnership #HealthcareSystems #Patients

Not only is today the "Perfect Date" 😉 It's also 📣 National DNA Day! 📣 Your DNA 🧬 can tell you so much about yourself. From learning about your ancestors and finding long lost relatives 🌎 (like with Ancestry) to determining the likelihood of can smell asparagus-related odor in your urine (👀23andMe) and even your risk factors for cancers. So I thought today would be the perfect day to share this study 🕵♀️: An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk. I have no affiliation with this study but I fully believe that knowledge is power 💪. So go to the link for more information and if you meet the inclusion criteria you should consider participating. https://lnkd.in/g8xRyVdx

How do I sum up #ACR2023? As a patient advocacy group, our experience is a little different than other attendees. The “patient voice” is a common thread woven throughout research, treatments, market access… so I felt very much like this weekend was spent sewing everything together to come out better than we started. I’m invigorated and hopeful! It’s definitely clear which companies are “checking the boxes” and those who are truly invested in patients. It’s an eco system that requires both top-down and trickle-up strategies. Kudos to those who are innovating not just in science, but also in patient engagement. Guess what? It’s working! And researchers, providers, payers… I’m talking to you too. Coffee stations and fresh baked brownies lure you in, but how are you helping patients get access to the treatments they need? We’re all in the together and I’m owning my piece of this by creating meaningful “patient voice” opportunities that are more than just checking a box. ✅ What piece are you owning? #patientadvocacy #lupus #patientengagement #pharmaceuticalindustry #partnershipsmatter https://lnkd.in/g7NHmj74

CDRC, Critical Path Institute (C-Path), and CURE ID team members will be traveling to Barcelona to attend the International Drug Repurposing Conference 2024 (#iDR24): Bridging boundaries for Innovative Drug Repurposing. Join them on 6-7 March 2024 at Sant Pau Art Nouveau World Heritage Site Sant for #iDR24, uniting key players in drug repurposing. Co-organized by REMEDi4ALL Consortium, Beacon for Rare Diseases, and MeRIT, the conference showcases how patient communities, researchers, industry, and health authorities can benefit from cutting-edge drug repurposing. The agenda follows 3 topical paths in parallel: · Cancer path · Rare diseases path · Methodologies path Explore cutting-edge insights, discuss challenges, and engage with experts. Find out more about the speakers, location, ticket prices and more here: https://lnkd.in/eRtYcAmZ Smith Heavner, PhD, RN| Marco Schito| Heather Stone| Shira Strongin| Keyla Tumas| REMEDi4ALL| Beacon for Rare Diseases| #REMEDi4ALL #Beacon #MeRIT #drugrepurposing #patientadvocacy

Exciting news! MPP, Unitaid, IAVI and Wellcome Trust have just published a paper in PLOS Global Public Health on "Novel Approaches to Enable Equitable Access to #MonoclonalAntibodies in Low- and Middle-Income Countries". The article addresses the challenges & discusses solutions for making monoclonal antibodies accessible and affordable in regions most in need. Join us in sharing this important work and advancing #GlobalHealth equity! Authors include Shelly Malhotra, Anne-Isabelle Cameron, Dzintars Gotham, Esteban Burrone, Pete Gardner, Colleen Loynachan, Sébastien Morin, Cherise Scott, and Carmen Pérez Casas. Read more > https://bit.ly/3LdmbQn

In our latest webinar, Sano Senior Project Manager Hayley Holt, PhD shares an in-depth look at Sano’s work on a clinical trial for Alpha-1 Antitrypsin Deficiency (AATD). Learn about the methodologies used and the impressive success metrics achieved. 📈 Read the recap or watch the webinar, available on-demand now. 👇 https://lnkd.in/emiGdShR #ClinicalTrials #PrecisionMedicine #RareDisease